Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176376 | 0.83 | SLC22A12 (0.59) | SLC22A12KEAP1NFE2L2 | |
| SCHEMBL31462450 | 0.82 | CHRNA7 (0.48) | SMN1; SMN2CYP2A6LMNAHPGD | |
| SCHEMBL3178992 | 0.80 | SLC22A12 (0.53) | SLC22A12SMN1; SMN2CYP2A6KEAP1NFE2L2 | |
| SCHEMBL156931 | 0.72 | CYP2A6 (0.69) | SLC22A12SMN1; SMN2CYP2A6KEAP1NFE2L2 | |
| SCHEMBL12180747 | 0.72 | POLB (0.70) | SMN1; SMN2LMNARAB9AHPGDPOLB | |
| SCHEMBL11977238 | 0.71 | SLC22A12 (1.00) | SLC22A12KEAP1NFE2L2 | |
| SCHEMBL4418009 | 0.70 | CYP2A6 (0.71) | SMN1; SMN2CYP2A6KEAP1NFE2L2CA2 | |
| SCHEMBL21938649 | 0.69 | SLC22A12 (0.45) | SLC22A12SMN1; SMN2CYP2A6KEAP1NFE2L2 | |
| SCHEMBL9883963 | 0.69 | CYP2A6 (0.65) | SLC22A12SMN1; SMN2CYP2A6KEAP1NFE2L2 | |
| SCHEMBL3082370 | 0.69 | SLC22A12 (0.47) | SLC22A12SMN1; SMN2CYP2A6KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096372-A1 | Small-molecule modulators of hepatocyte growth factor/scatter factor activities | PILLARISETTI SIVARAM (US) | 2005-05-05 | — | — | US | disclosed |
| US-6855728-B2 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2005-02-15 | — | — | US | disclosed |
| US-6589997-B2 | 1-Phenylprop-2-en-1-one derivatives as wound healing, anticarcinogenic, antiarthritic, antitumor, antiproliferative, antiinflammatory or antimetastasis agents | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096372-A1 | Small-molecule modulators of hepatocyte growth factor/scatter factor activities | HGF, HDGF, MET | SLC22A12 2181/4885SMN1; SMN2 3351/4885CYP2A6 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.